Roy N Alcalay1, Elise Caccappolo2, Helen Mejia-Santana2, Ming Xin Tang1, Llency Rosado2, Martha Orbe Reilly2, Diana Ruiz2, Elan D Louis3, Cynthia L Comella4, Martha A Nance5, Susan B Bressman6, William K Scott7, Caroline M Tanner8, Susan F Mickel9, Cheryl H Waters2, Stanley Fahn2, Lucien J Cote10, Steven J Frucht2, Blair Ford2, Michael Rezak11, Kevin E Novak12, Joseph H Friedman13, Ronald F Pfeiffer14, Laura Marsh15, Bradley Hiner16, Haydeh Payami17, Eric Molho18, Stewart A Factor19, John G Nutt20, Carmen Serrano21, Maritza Arroyo21, Ruth Ottman22, Michael W Pauciulo23, William C Nichols23, Lorraine N Clark24, Karen S Marder3. 1. Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York2Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York. 2. Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York. 3. Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York2Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York3Gertru. 4. Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois. 5. Struthers Parkinson's Center, Park Nicollet Clinic, Golden Valley, Minnesota. 6. The Alan and Barbara Mirken Department of Neurology, Beth Israel Medical Center, New York, New York8Department of Neurology, Albert Einstein College of Medicine, Bronx, New York. 7. Dr John T. Macdonald Foundation, Department of Human Genetics, Miami Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida. 8. Parkinson's Institute, Sunnyvale, and Department of Health Research and Policy, Stanford University, Palo Alto, California. 9. Marshfield Clinic, Department of Neurology, Marshfield, Wisconsin. 10. Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York3Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York. 11. Central DuPage Hospital, Neurosciences Institute, Movement Disorders Center, Winfield, Illinois. 12. Department of Neurology, NorthShore University Health System, Evanston, Illinois14Department of Neurology, University of Chicago, Pritzker School of Medicine, Chicago, Illinois. 13. Department of Neurology, Butler Hospital, Providence, Rhode Island16Department of Neurology, Alpert Medical School, Brown University, Providence, Rhode Island. 14. Department of Neurology, College of Medicine, University of Tennessee Health Science Center, Memphis. 15. Morris K. Udall Parkinson's Disease Research Center of Excellence and Departments of Psychiatry and Behavioral Sciences and Neurology and Neurological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. 16. Department of Neurology, Medical College of Wisconsin, Milwaukee. 17. New York State Department of Health Wadsworth Center, Albany, New York. 18. Parkinson's Disease and Movement Disorders Center of Albany Medical Center, Albany, New York. 19. Department of Neurology, Emory University, Atlanta, Georgia. 20. Portland VA Medical Center, Parkinson Disease Research, Education and Clinical Center, and Oregon Health and Science University, Portland. 21. Department of Neurology, University of Puerto Rico, San Juan. 22. Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York3Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York4Department of Epidemiology, Mailman School of P. 23. Division of Human Genetics, Cincinnati Children's Hospital Medical Center, and Department of Pediatrics; University of Cincinnati College of Medicine, Ohio. 24. Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York27Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New Yor.
Abstract
IMPORTANCE: Data on the long-term cognitive outcomes of patients with PARKIN-associated Parkinson disease (PD) are unknown but may be useful when counseling these patients. OBJECTIVE: Among patients with early-onset PD of long duration, we assessed cognitive and motor performances, comparing homozygotes and compound heterozygotes who carry 2 PARKIN mutations with noncarriers. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study of 44 participants at 17 different movement disorder centers who were in the Consortium on Risk for Early-Onset PD study with a duration of PD greater than the median duration (>14 years): 4 homozygotes and 17 compound heterozygotes (hereafter referred to as carriers) and 23 noncarriers. MAIN OUTCOMES AND MEASURES: Unified Parkinson Disease Rating Scale Part III (UPDRS-III) and Clinical Dementia Rating scores and neuropsychological performance. Linear regression models were applied to assess the association between PARKIN mutation status and cognitive domain scores and UPDRS-III scores. Models were adjusted for age, education, disease duration, language, and levodopa equivalent daily dose. RESULTS: Carriers had an earlier age at onset of PD (P < .001) and were younger (P = .004) at time of examination than noncarriers. They performed better than noncarriers on the Mini-Mental State Examination (P = .010) and were more likely to receive lower scores on the Clinical Dementia Rating (P = .003). In multivariate analyses, carriers performed better than noncarriers on the UPDRS-III (P = .02) and on tests of attention (P = .03), memory (P = .03), and visuospatial (P = .02) cognitive domains. CONCLUSIONS AND RELEVANCE: In cross-sectional analyses, carriers demonstrated better cognitive and motor performance than did noncarriers with long disease duration, suggesting slower disease progression. A longitudinal follow-up study is required to confirm these findings.
IMPORTANCE: Data on the long-term cognitive outcomes of patients with PARKIN-associated Parkinson disease (PD) are unknown but may be useful when counseling these patients. OBJECTIVE: Among patients with early-onset PD of long duration, we assessed cognitive and motor performances, comparing homozygotes and compound heterozygotes who carry 2 PARKIN mutations with noncarriers. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study of 44 participants at 17 different movement disorder centers who were in the Consortium on Risk for Early-Onset PD study with a duration of PD greater than the median duration (>14 years): 4 homozygotes and 17 compound heterozygotes (hereafter referred to as carriers) and 23 noncarriers. MAIN OUTCOMES AND MEASURES: Unified Parkinson Disease Rating Scale Part III (UPDRS-III) and Clinical Dementia Rating scores and neuropsychological performance. Linear regression models were applied to assess the association between PARKIN mutation status and cognitive domain scores and UPDRS-III scores. Models were adjusted for age, education, disease duration, language, and levodopa equivalent daily dose. RESULTS: Carriers had an earlier age at onset of PD (P < .001) and were younger (P = .004) at time of examination than noncarriers. They performed better than noncarriers on the Mini-Mental State Examination (P = .010) and were more likely to receive lower scores on the Clinical Dementia Rating (P = .003). In multivariate analyses, carriers performed better than noncarriers on the UPDRS-III (P = .02) and on tests of attention (P = .03), memory (P = .03), and visuospatial (P = .02) cognitive domains. CONCLUSIONS AND RELEVANCE: In cross-sectional analyses, carriers demonstrated better cognitive and motor performance than did noncarriers with long disease duration, suggesting slower disease progression. A longitudinal follow-up study is required to confirm these findings.
Authors: C B Lücking; A Dürr; V Bonifati; J Vaughan; G De Michele; T Gasser; B S Harhangi; G Meco; P Denèfle; N W Wood; Y Agid; A Brice Journal: N Engl J Med Date: 2000-05-25 Impact factor: 91.245
Authors: L N Clark; Y Wang; E Karlins; L Saito; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder Journal: Neurology Date: 2006-10-18 Impact factor: 9.910
Authors: Karina Sakanaka; Cheryl H Waters; Oren A Levy; Elan D Louis; Wendy K Chung; Karen S Marder; Roy N Alcalay Journal: J Genet Couns Date: 2013-06-09 Impact factor: 2.537
Authors: K Hedrich; K Marder; J Harris; M Kann; T Lynch; H Meija-Santana; P P Pramstaller; E Schwinger; S B Bressman; S Fahn; C Klein Journal: Neurology Date: 2002-04-23 Impact factor: 9.910
Authors: Ebba Lohmann; Magali Periquet; Vincenzo Bonifati; Nick W Wood; Giuseppe De Michele; Anne-Marie Bonnet; Valérie Fraix; Emmanuel Broussolle; Martin W I M Horstink; Marie Vidailhet; Patrice Verpillat; Thomas Gasser; David Nicholl; Hélio Teive; Salmo Raskin; Olivier Rascol; Alain Destée; Merle Ruberg; Francesca Gasparini; Giuseppe Meco; Yves Agid; Alexandra Durr; Alexis Brice Journal: Ann Neurol Date: 2003-08 Impact factor: 10.422
Authors: Naheed L Khan; Elizabeth Graham; Peter Critchley; Anette E Schrag; Nicholas W Wood; Andrew J Lees; Kailash P Bhatia; Niall Quinn Journal: Brain Date: 2003-06 Impact factor: 13.501
Authors: Madeleine E Sharp; Elise Caccappolo; Helen Mejia-Santana; Ming-X Tang; Llency Rosado; Martha Orbe Reilly; Diana Ruiz; Elan D Louis; Cynthia Comella; Martha Nance; Susan Bressman; William K Scott; Caroline Tanner; Cheryl Waters; Stanley Fahn; Lucien Cote; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Haydeh Payami; Eric Molho; Stuart A Factor; John Nutt; Carmen Serrano; Maritza Arroyo; Michael W Pauciulo; William C Nichols; Lorraine N Clark; Roy N Alcalay; Karen S Marder Journal: Mov Disord Date: 2014-11-12 Impact factor: 10.338
Authors: Fatemeh Noohi; Nate B Boyden; Youngbin Kwak; Jennifer Humfleet; Martijn L T M Müller; Nicolaas I Bohnen; Rachael D Seidler Journal: Neuropsychologia Date: 2016-02-27 Impact factor: 3.139
Authors: Gian D Pal; Deborah Hall; Bichun Ouyang; Jessica Phelps; Roy Alcalay; Michael W Pauciulo; William C Nichols; Lorraine Clark; Helen Mejia-Santana; Lucia Blasucci; Christopher G Goetz; Cynthia Comella; Amy Colcher; Ziv Gan-Or; Guy A Rouleau; Karen Marder Journal: Mov Disord Clin Pract Date: 2016-01-18
Authors: Francesca Morgante; Alfonso Fasano; Monia Ginevrino; Simona Petrucci; Lucia Ricciardi; Francesco Bove; Chiara Criscuolo; Marcello Moccia; Anna De Rosa; Chiara Sorbera; Anna Rita Bentivoglio; Paolo Barone; Giuseppe De Michele; Maria Teresa Pellecchia; Enza Maria Valente Journal: Neurology Date: 2016-09-02 Impact factor: 9.910
Authors: Madeleine E Sharp; Karen S Marder; Lucien Côté; Lorraine N Clark; William C Nichols; Jean-Paul Vonsattel; Roy N Alcalay Journal: Mov Disord Date: 2013-12-27 Impact factor: 10.338
Authors: Suzanne Lesage; Ariane Lunati; Marion Houot; Sawssan Ben Romdhan; Fabienne Clot; Christelle Tesson; Graziella Mangone; Benjamin Le Toullec; Thomas Courtin; Kathy Larcher; Mustapha Benmahdjoub; Mohammed Arezki; Ahmed Bouhouche; Mathieu Anheim; Emmanuel Roze; François Viallet; François Tison; Emmanuel Broussolle; Murat Emre; Hasmet Hanagasi; Basar Bilgic; Meriem Tazir; Mouna Ben Djebara; Riadh Gouider; Christine Tranchant; Marie Vidailhet; Eric Le Guern; Olga Corti; Chokri Mhiri; Ebba Lohmann; Andrew Singleton; Jean-Christophe Corvol; Alexis Brice Journal: Ann Neurol Date: 2020-05-30 Impact factor: 10.422
Authors: Suzanne Lesage; Ariane Lunati; Marion Houot; Sawssan Ben Romdhan; Fabienne Clot; Christelle Tesson; Graziella Mangone; Benjamin Le Toullec; Thomas Courtin; Kathy Larcher; Mustapha Benmahdjoub; Mohamed Arezki; Ahmed Bouhouche; Mathieu Anheim; Emmanuel Roze; François Viallet; François Tison; Emmanuel Broussolle; Murat Emre; Hasmet Hanagasi; Basar Bilgic; Meriem Tazir; Mouna Ben Djebara; Riadh Gouider; Christine Tranchant; Marie Vidailhet; Eric Le Guern; Olga Corti; Chokri Mhiri; Ebba Lohmann; Andrew Singleton; Jean-Christophe Corvol; Alexis Brice Journal: Ann Neurol Date: 2020-07-28 Impact factor: 11.274